AB — AB Science SA Share News
0.000.00%
Last trade - 00:00- €65.08m
- €73.85m
- €1.17m
French and Benelux stocks-Factors to watch
Brief: AB Science H1 Operating Loss Widens To 9.6 Million Euros
French and Benelux stocks-Factors to watch
Brief: AB Science Gets Positive Recommendation For masitinib In COVID-19 Study
Brief: AB Science Says It Has Filed Application For Conditional Marketing Authorization To EMA For Masitinib
Brief: AB Science SA - Announces Health Canada Issued Screening Acceptance Letter For Application Of Masitinib In Treatment Of Amyotrophic Lateral Sclerosis
Brief: AB Science FY Operating Loss Narrows To EUR 13.8 Mln
Brief: AB Science Announced The Continuation Of The Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin In Covid-19
Brief: AB Science Considers Appealing AMF Decision On Possible Insider Trading
Brief: AB Science To Issue Convertible Bonds With Attached Warrants Worth USD 8.5 Mln
Brief: AB Science Reports Positive Trial Results On Mastinib In Progressive Forms Of Multiple Sclerosis
Brief: AB Science Authorised To File New Drug Submission For masitinib
Brief: AB Science Issues Clarification Following Feb 11, 2022 Public Hearing Of Enforcement Committee Of French Market Regulator
French and Benelux stocks-Factors to watch
French and Benelux stocks-Factors to watch
Brief: AB Science Authorised To Initiate Confirmatory Phase III Trial Of Masitinib In Progressive Forms Of Multiple Sclerosis
Brief: AB Science Authorised To Initiate Phase II Study In Patients With Severe Mast Cell Activation Syndrome
Brief: AB Science Granted Authorization By ANSM To Initiate Confirmatory Phase III Trial Of Masitinib In Progressive Forms Of Multiple Sclerosis
Brief: AB Science Gets FDA Authorisation For New Trial In Leukemia